Contrast-enhanced ultrasound in the diagnosis of liver diseases - Tracing the history and perspective

Kanzo/Acta Hepatologica Japonica

Volumn 50, Issue 3, 2009, Pages 105-121

  Iijima, Hiroko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Contrast ultrasound; Kupffer image; Liver diseases; Liver tumor; Microbubble

Indexed keywords

ALBUNEX; CONTRAST MEDIUM; PERFLUBUTANE; PERFLUTREN; SHU 508; SONOVUE;

CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; LIVER DISEASE; REVIEW;

EID: 66149184554     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.50.105     Document Type: Review

References (197)

1. Gramiak R, Shah PM, Kramer DH. Ultrasound cardiography: contrast studies in anatomy and function. Radiology 1969; 92: 939-948
2. Feigenba H, Stone JM, Lee DA, et al. Identification of ultrasound echoes from the left ventricle by use of intracardiac injections of indocyanine green. Circulation 1970; 41:615-621
3. Kerber RE, Dippel WF, Abboud FM. Abnormal motion of the interventricular septum in right ventricular volume overload. Experimental and clinical echocardiographic studies. Circulation 1973; 48: 86-96
4. Kerber RE, Kioschos JM, Lauer RM. Use of an ultrasonic contrast method in the diagnosis of valvular regurgitation and intracardiac shunts. Am J Cardiol 1974; 34: 722-727
5. Seward JB, Tajik AJ, Spangler JG, et al. Echocardiographic contrast studies: initial experience. Mayo Clin Proc 1975; 50: 163-192
6. Seward JB, Tajik AJ, Hagler DJ, et al. Contrast echocardiography in single or common ventricle. Circulation 1977; 55: 513-519
7. 7) Serruys PW, Vandenbrand M, Hugenholtz PG, et al. Intracardiac right-to-left shunts demonstrated by two-dimensional echocardiography after peripheral vein injection. Br Heart J 1979; 42: 429-437
8. Meltzer RS, Tickner EG, Sahines TP, et al. The source of ultrasound contrast effect. J Clin Ultrasound 1980; 8: 121-127
9. DeMaria AN, Bommer W, Takeda P, et al. Value and limitations of contrast echocardiography in cardiac diagnosis. Cardiovasc Clin 1983; 13: 167-179
10. Klicpera M, Glogar D, Mayr H, et al. Myocardial perfusion evaluated by contrast echocardiography. A preliminary report. Chest 1982; 82: 751-756
11. Munoz S, Berti C, Pulido C, et al. Two-dimensional contrast echocardiography with carbon dioxide in the detection of congenital cardiac shunts. Am J Cardiol 1984; 53: 206-210
12. 2 microbubbles. Radiology 1986; 161: 701-705
13. Kudo M, Tomita S, Tochio H, et al. Hepatic focal nodular hyperplasia: specific findings at dynamic contrast-enhanced US with carbon dioxide microbubbles. Radiology 1991; 179: 377-382
14. 2 microbubbles. Radiology 1992; 182: 155-160
15. Kudo M, Tomita S, Tochio H, et al. Sonography with intraarterial infusion of carbon dioxide microbubbles (sonographic angiography): value in differential diagnosis of hepatic tumors. AJR Am J Roentgenol 1992; 158: 65-74
16. Nomura Y, Matsuda Y, Yabuuchi I, et al. Hepatocellular carcinoma in adenomatous hyperplasia: detection with contrast-enhanced US with carbon dioxide microbubbles. Radiology 1993; 187: 353-356
17. Elmouaaouy A, Naruhn M, Becker HD, et al. Intraoperative echo-contrast ultrasound examination of malignant liver neoplasms - initial clinical experience. Surg Endosc 1991; 5: 214-218
18. Christiansen C, Kryvi H, Sontum PC, et al. Physical and biochemical characterization of Albunex, a new ultrasound contrast agent consisting of airfilled albumin microspheres suspended in a solution of human albumin. Biotechnol Appl Biochem 1994; 19: 307-320
19. 19) Grayburn PA, Weiss JL, Hack TC, et al. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. J Am Coll Cardiol 1998; 32: 230-236 (Pubitemid 28351067)
20. Keller MW, Glasheen W, Kaul S. Albunex: a safe and effective commercially produced agent for myocardial contrast echocardiography. J Am Soc Echocardiogr 1989; 2: 48-52
21. Hilpert PL, Mattrey RF, Mitten RM, et al. IV injection of air-filled human albumin microspheres to enhance arterial Doppler signal: a preliminary study in rabbits. AJR Am J Roentgenol 1989; 153: 613-616
22. Smith MD, Elion JL, McClure RR, et al. Left heart opacification with peripheral venous injection of a new saccharide echo contrast agent in dogs. J Am Coll Cardiol 1989; 13: 1622-1628
23. Schlief R. Ultrasound contrast agents. Curr Opin Radiol 1991; 3: 198-207
24. Uchimoto R, Niwa K, Eguchi H, et al. In vivo kinetics of microbubbles of SHU 508 A (Levovist): Comparison with Indocyanine Green in rabbits. Ultrasound Med Biol 1999; 25: 1365-1370
25. Leen E, Angerson WJ, Warren HW, et al. Improved sensitivity of colour Doppler flow imaging of colorectal hepatic metastases using galactose microparticles: a preliminary report. Br J Surg 1994; 81: 252-254
26. Fujimoto M, Moriyasu F, Nishikawa K, et al. Color Doppler sonography of hepatic tumors with a galactose-based contrast agent: correlation with angiographic findings. AJR Am J Roentgenol 1994; 163: 1099-1104
27. Tanaka S, Kitamra T, Yoshioka F, et al. Effectiveness of galactose-based intravenous contrast medium on color Doppler sonography of deeply located hepatocellular carcinoma. Ultrasound Med Bio 1995; 21: 157-160
28. Ernst H, Hahn EG, Balzer T, et al. Color Doppler ultrasound of liver lesions: Signal enhancement after intravenous injection of the ultrasound contrast agent Levovist. J Clin Ultrasound 1996; 24: 31-35
29. Sitzer M, Furst G, Siebler M, et al. Usefulness of an intravenous contrast medium in the characterization of high-grade internal carotid stenosis with color Doppler-assisted duplex imaging. Stroke 1994; 25: 385-389
30. Bogdahn U, Frohlich T, Becker G, et al. Vascularization of primary central nervous system tumors: detection with contrast-enhanced transcranial color-coded real-time sonography. Radiology 1994; 192: 141-148
31. Schwarz KQ, Becher H, Schimpfky C, et al. Doppler enhancement with SH U 508A in multiple vascular regions. Radiology 1994; 193: 195-201
32. Bogdahn U, Becker G, Schlief R, et al. Contrast-enhanced transcranial color-coded real-time sonography. Results of a phase-two study. Stroke 1993; 24: 676-684
33. 33) Becker G, Lindner A, Bogdahn U. Imaging of the vertebrobasilar system by transcranial color-coded real-time sonography. J Ultrasound Med 1993; 12: 395-401 (Pubitemid 23199308)
34. Suren A, Osmers R, Kulenkampff D, et al. Visualization of blood flow in small ovarian tumor vessels by transvaginal color Doppler sonography after echo enhancement with injection of Levovist. Gynecol Obstet Invest 1994; 38: 210-212
35. Cennamo G, Rosa N, Vallone GF, et al. First experience with a new echographic contrast agent. Br J Ophthalmol 1994; 78: 823-826
36. Otis S, Rush M, Boyajian R. Contrast-enhanced transcranial imaging. Results of an American phase-two study. Stroke 1995; 26: 203-209
37. Missouris CG, Allen CM, Balen FG, et al. Non-invasive screening for renal artery stenosis with ultrasound contrast enhancement. J Hyperten 1996; 14: 519-524
38. 38) Kedar RP, Cosgrove D, McCready VR, et al. Microbubble contrast agent for color Doppler US: Effect on breast masses. Radiology 1996; 198: 679-686 (Pubitemid 26066281)
39. 39) Bhutani MS, Hoffman BJ, vanVelse A, et al. Contrast-enhanced endoscopic ultrasonography with galactose microparticles: SHU508 A (Levovist). Endoscopy 1997; 29: 635-639
40. Huber S, Helbich T, Kettenbach J, et al. Effects of a microbubble contrast agent on breast tumors: Computer-assisted quantitative assessment with color Doppler US-Early experience. Radiology 1998; 208: 485-489
41. 41) Postert T, Braun B, Federlein J, et al. Diagnosis and monitoring of middle cerebral artery occlusion with contrast-enhanced transcranial color-coded real-time sonography in patients with inadequate acoustic bone windows. Ultrasound Med Biol 1998; 24: 333-340
42. 42) Claudon M, Plouin PF, Baxter GM, et al. Renal arteries in patients at risk of renal arterial stenosis: Multicenter evaluation of the echo-enhancer SHU 508A at color and spectral Doppler US. Radiology 2000; 214: 739-746 (Pubitemid 30115374)
43. 43) Koga M, Kimura K, Minematsu K, et al. Relationship between findings of conventional and contrast-enhanced transcranial color-coded real-time sonography and angiography in patients with basilar artery occlusion. AJNR Am J Neuroradiol 2002; 23: 568-571 (Pubitemid 34411909)
44. Kitzman DW, Goldman ME, Gillam LD, et al. Efficacy and safety at the novel ultrasound contrast agent Perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000; 86: 669-674
45. 45) Leen E, Angerson WJ, Yarmenitis S, et al. Multicentre clinical study evaluating the efficacy of SonoVue (BRI), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002; 41: 200-206
46. 46) Krix M, Kiessling F, Essig M, et al. Low mechanical index contrast-enhanced ultrasound better reflects high arterial perfusion of liver metastases than arterial phase computed tomography. Invest Radiol 2004; 39: 216-222 (Pubitemid 38391786)
47. 47) Maruyama H, Matsutani S, Saisho H, et al. Different behaviors of microbubbles in the liver: Time-related quantitative analysis of two ultrasound contrast agents, Levovist and Definity. Ultrasound Med Bio 2004; 30: 1035-1040 (Pubitemid 39330592)
48. 48) Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-426 (Pubitemid 39158751)
49. Ohkusa A, Yoshioka H, Okafuji T, et al. Evaluation of US contrast medium (LEVOVIST) to experimental liver cancer. Nippon Acta Radiologica 1992; 52: 1024-1026
50. Goldberg BB, Liu JB, Burns PN, et al. Galactose-based intravenous sonographic contrast agent: experimental studies. J Ultrasound Med 1993; 12: 463-470
51. Rosenkranz K, Zendel W, Langer R, et al. Contrast-enhanced transcranial Doppler US with a new transpulmonary echo contrast agent based on saccharide microparticles. Radiology 1993; 187: 439-443
52. Kim AY, Choi BI, Kim TK, et al. Hepatocellular carcinoma: Power Doppler US with a contrast agent-Preliminary results. Radiology 1998; 209: 135-140
53. 53) Kamiyama N, Moriyasu F, Mine Y, et al. Analysis of flash echo from contrast agent for designing optimal ultrasound diagnostic systems. Ultrasound Med Biol 1999; 25: 411-420 (Pubitemid 29191185)
54. Moriyasu F, Kono Y, Nada T, et al. Flash echo (passive cavitation) imaging of the liver by using US contrast agents and intermittent scanning sequence. Radiology 1996; 201: 374-1374
55. Hosten N, Puls R, Lemke AJ, et al. Contrast-enhanced power Doppler sonography: Improved detection of characteristic flow patterns in focal liver lesions. J Clin Ultrasound 1999; 27: 107-115
56. 56) Uggowitzer M, Kugler C, Groll R, et al. Sonographic evaluation of focal nodular hyperplasias (FNH) of the liver with a transpulmonary galactose-based contrast agent (Levovist). Br J Radiol 1998; 71: 1026-1032 (Pubitemid 28473078)
57. 57) Bartolozzi C, Lencioni R, Ricci P, et al. Hepatocellular carcinoma treatment with percutaneous ethanol injection: Evaluation with contrast-enhanced color Doppler US. Radiology 1998; 209: 387-393 (Pubitemid 28503103)
58. Tanaka S, Kitamra T, Fujita M, et al. Value of contrast-enhanced color Doppler sonography in diagnosing: Hepatocellular carcinoma with special attention to the "color-filled pattern". J Clin Ultrasound 1998; 26: 207-212
59. 59) Fracanzani AL, Burdick L, Borzio M, et al. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001; 34: 1109-1112 (Pubitemid 33096582)
60. Kim TK, Han JK, Kim AY, et al. Limitations of characterization of hepatic hemangiomas using a sonographic contrast agent (Levovist) and power Doppler ultrasonography. J Ultrasound Med 1999; 18: 737-743
61. Wu JY, Shung KK. Nonlinear energy exchange among harmonic modes and its applications to nonlinear imaging. J Acoust Soc Am 1990; 88: 2852-2858
62. 62) Ward B, Baker AC, Humphrey VF. Nonlinear propagation applied to the improvement of resolution in diagnostic medical ultrasound. J Acoust Soc Am 1997; 101: 143-154 (Pubitemid 27026624)
63. 63) Shapiro RS, Wagreich J, Parsons RB, et al. Tissue harmonic imaging sonography: Evaluation of image quality compared with conventional sonography. AJR Am J Roentgenol 1998; 171: 1203-1206 (Pubitemid 28489397)
64. 64) Tranquart F, Grenier N, Eder V, et al. Clinical use of ultrasound tissue harmonic imaging. Ultrasound Med Biol 1999; 25: 889-894 (Pubitemid 29325761)
65. Kono Y, Moriyasu F, Nada T, et al. Gray scale second harmonic imaging of the liver: A preliminary animal study. Ultrasound Med Biol 1997; 23: 719-726
66. Kono Y, Moriyasu F, Mine Y, et al. Gray-scale second harmonic imaging of the liver with galactose-based microbubbles. Invest Radiol 1997; 32: 120-125
67. Blomley M, Albrecht T, Cosgrove D, et al. Stimulated acoustic emission imaging ("sono-scintigraphy") with the ultrasound contrast agent Levovist: A reproducible Doppler ultrasound effect with potential clinical utility. Acad Radiol 1998; 5: S236-S239
68. 68) Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508 A: Early experience. Radiology 1999; 210: 409-416 (Pubitemid 29055309)
69. Blomley MJ, Albrecht T, Cosgrove DO, et al. Stimulated acoustic emission to image a late liver and spleen-specific phase of Levovist in normal volunteers and patients with and without liver disease. Ultrasound Med Biol 1999; 25: 1341-1352
70. Suzuki S, Iijima H, Moriyasu F, et al. Differential diagnosis of hepatic nodules using delayed parenchymal phase imaging of levovist contrast ultrasound: comparative study with SPIO-MRI. Hepatol Res 2004; 29: 122-126
71. 71) Youk JH, Lee JM, Kim CS. Therapeutic response evaluation of malignant hepatic masses treated by interventional procedures with contrast-enhanced agent detection imaging. J Ultrasound Med 2003; 22: 911-920 (Pubitemid 37082558)
72. Shimizu M, Iijima H, Horibe T, et al. Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res 2004; 29: 235-242
73. Kim CK, Choi DG, Lim HK, et al. Therapeutic response assessment of percutaneous radio frequency ablation for hepatocellular carcinoma: Utility of contrast-enhanced agent detection imaging. Eur J Radiol 2005; 56: 66-73
74. Kindberg GM, Tolleshaug H, Roos N, et al. Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res 2003; 312: 49-54
75. Blomley MJ, Sidhu PS, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early experience. Radiology 2001; 220: 661-667
76. Iijima H, Moriyasu F, Miyahara T, et al. Ultrasound contrast agent, Levovist microbubbles are phagocytosed by Kupffer cells - In vitro and in vivo studies. Hepatol Res 2006; 35: 235-237
77. Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007; 33: 318-325
78. Watanabe R, Matsumura M, Munemasa T, et al. Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography-Microscopic studies in rat liver. Invest Radiol 2007; 42: 643-651
79. Maruyama H, Matsutani S, Saisho H, et al. Real-time blood-pool images of contrast enhanced ultrasound with Definity in the detection of tumour nodules in the liver. Br J Radiol 2005; 78: 512-518
80. Schneider M, Arditi M, Barrau MB, et al. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Investigative Radiology 1995; 30: 451-457
81. 81) Senior P, Andersson O, Caidahl K, et al. Enhanced left ventricular endocardial border delineation with an intravenous injection of SonoVue, a new echocardiographic contrast agent: A European multicenter study. Echocardiography 2000; 17: 705-711
82. Lim AK, Patel N, Eckersley RJ, et al. Evidence for spleen-specific uptake of a microbubble contrast agent: A quantitative study in healthy volunteers. Radiology 2004; 231: 785-788
83. Uran S, Landmark K, Normann PT, et al. A respiration-metabolism chamber system and a GC-MS method developed for studying exhalation of perfluorobutane in rats after intravenous injection of the ultrasound contrast agent Sonazoid. J Pharm Biomed Anal 2005; 39: 746-751
84. Shigeta K, Taniguchi N, Omoto K, et al. In vitro platelet activation by an echo contrast agent. J Ultrasound Med 2003; 22: 365-373
85. Shigeta K, Itoh K, Ookawara S, et al. The effects of Levovist and DD 723 in activating platelets and damaging hepatic cells of rats. J Ultrasound Med 2005; 24: 967-974
86. ter Haar GR. Ultrasonic contrast agents: safety considerations reviewed. Eur J Radiol 2002; 41: 217-221
87. Landmark KE, Johansen PW, Johnson JA, et al. Pharmacokinetics of perfluorobutane following intravenous bolus injection and continuous infusion of sonazoid in healthy volunteers and in patients with reduced pulmonary diffusing capacity. Ultrasound Med Biol 2008; 34: 494-501
88. Liu GJ, Moriyasu F, Hirokawa T, et al. Optical Microscopic Findings of the Behavior of Perflubutane Microbubbles Outside and Inside Kupffer Cells During Diagnostic Ultrasound Examination. Invest Radiol 2008; 43: 829-836
89. Fowlkes JB, Holland CK. Mechanical bioeffects from diagnostic ultrasound: AIUM consensus statements-Introduction. J Ultrasound Med 2000; 19: 69-72
90. 90) Shi WT, Forsberg F. Ultrasonic characterization of the nonlinear properties of contrast microbubbles. Ultrasound Med Biol 2000; 26: 93-104 (Pubitemid 30045527)
91. 91) Sheiner E, Freeman J, Abramowicz JS. Acoustic output as measured by mechanical and thermal indices during routine obstetric ultrasound examinations. J Ultrasound Med 2005; 24: 1665-1670 (Pubitemid 41780710)
92. 92) Sboros V, Moran CM, Pye SD, et al. The behaviour of individual contrast agent microbubbles. Ultrasound Med Biol 2003; 29: 687-694 (Pubitemid 36566546)
93. Miller DL, Averkiou MA, Brayman AA, et al. Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med 2008; 27: 611-632
94. Maruyama H, Matsutani S, Saisho H, et al. Greyscale contrast enhancement in rabbit liver with DMP115 at different acoustic power levels. Ultrasound Med Biol 2000; 26: 1429-1438
95. Edey AJ, Ryan SM, Beese RC, et al. Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging. Clin Radiol 2008; 63: 1112-1120
96. Sontum PC, Ostensen J, Dyrstad K, et al. Acoustic properties of NC100100 and their relation with the microbubble size distribution. Invest Radiol 1999; 34: 268-275
97. Emmer M, Vos HJ, Goertz DE, et al. Pressure-dependent attenuation and scattering of phospholipid-coated microbubbles at low acoustic pressures. Ultrasound Med Biol 2009; 35: 102-111
98. Shi WT, Forsberg F, Tornes A, et al. Destruction of contrast microbubbles and the association with inertial cavitation. Ultrasound Med Biol 2000; 26: 1009-1019
99. 99) Forsberg F, Shi WT, Merritt CRB, et al. On the usefulness of the mechanical index displayed on clinical ultrasound scanners for predicting contrast microbubble destruction. J Ultrasound Med 2005; 24: 443-450 (Pubitemid 40470890)
100. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radiol 2006; 60: 324-330
101. Kitamura H, Kawasaki S, Nakajima K, et al. Correlation between microbubble contrast-enhanced color Doppler sonography and immunostaining for Kupffer cells in assessing the histopathologic grade of hepatocellular carcinoma: Preliminary results. J Clin Ultrasound 2002; 30: 465-471
102. 102) Burns PN, Wilson SR, Simpson DH. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol 2000; 35: 58-71 (Pubitemid 30033608)
103. 103) Albrecht T, Hoffmann CW, Schettler S, etal. B-mode enhancement at phase-inversion US with air-based microbubble contrast agent: Initial experience in humans. Radiology 2000; 216: 273-278
104. Kim AY, Choi BI, Kim TK, et al. Comparison of contrast-enhanced fundamental imaging, second-harmonic imaging, and pulse-inversion harmonic imaging. Investigative Radiology 2001; 36: 582-588
105. 105) Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol 2006; 186: 1401-1412 (Pubitemid 46115735)
106. Wilson SR, Burns PN. Liver mass evaluation with ultrasound: The impact of microbubble contrast agents and pulse inversion imaging. Semin Liver Dis 2001; 21: 147-159
107. 107) Eckersley RJ, Chin CT, Burns PN. Optimising phase and amplitude modulation schemes for imaging microbubble contrast agents at low acoustic power. Ultrasound Med Biol 2005; 31: 213-219 (Pubitemid 40228777)
108. 108) Leavens C, Williams R, Foster FS, et al. Golay pulse encoding for microbubble contrast imaging in ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control 2007; 54: 2082-2090 (Pubitemid 350249435)
109. Porter TR, Oberdorfer J, Rafter P, et al. Microbubble responses to a similar mechanical index with different real-time perfusion imaging techniques. Ultrasound Med Biol 2003; 29: 1187-1192
110. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-483
111. Muradali D, Kulkarni SR, Villet C, et al. Angiogenesis mapping with pulse inversion: A new and sensitive method to image vascularity in breast carcinomas. Radiology 2002; 225: 367-1367
112. Wilson SR, Jang HJ, Kim TK, et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol 2008; 190: 691-695
113. Yang H, Liu GJ, Lu MD, et al. Evaluation of the vascular architecture of hepatocellular carcinoma by micro flow imaging-Pathologic correlation. J Ultrasound Med 2007; 26: 461-467
114. Sugimoto K, Moriyasu F, Kamiyama N, et al. Analysis of morphological vascular changes of hepatocellular carcinoma by microflow imaging using contrast-enhanced sonography. Hepatol Res 2008; 38: 790-799
115. Sehgal CM, Cary TW, Arger PH, et al. Delta-projection Imaging on Contrast-enhanced Ultrasound to Quantify Tumor Microvasculature and Perfusion. Acad Radiol 2009; 16: 71-78
116. Sugimoto K, Moriyasu F, Kamiyama N, et al. Correlation between parametric imaging using contrast ultrasound and the histological differentiation of hepatocellular carcinoma. Hepatol Res 2008; 38: 273-280
117. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246: 508-518
118. Kruskal JB. Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies? Radiology 2008; 246: 339-340
119. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008; 43: 100-111
120. Harvey CJ, Blomley MJ, Eckersley RJ, et al. Pulse-inversion mode imaging of liver specific microbubbles: improved detection of subcentimetre metastases. Lancet 2000; 355: 807-808
121. Kim TK, Choi BI, Han JK, et al. Hepatic tumors: Contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology 2000; 216: 411-417
122. Choi BI, Kim TK, Han JK, et al. Vascularity of hepatocellular carcinoma: Assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology 2000; 214: 381-386
123. 123) Ding H, Kudo M, Onda H, et al. Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: Comparison with dynamic CT. Radiology 2001; 221: 721-730 (Pubitemid 33101764)
124. Celik H, Ozdemir H, Yucel C, et al. Characterization of hyperechoic focal liver lesions-Quantitative evaluation with pulse inversion harmonic imaging in the late phase of Levovist. J Ultrasound Med 2005; 24: 39-47
125. Ogawa S, Kumada T, Toyoda H, et al. Evaluation of pathological features of hepatocellular carcinoma by contrast-enhanced ultrasonography: Comparison with pathology on resected specimen. Eur J Radiol 2006; 59: 74-81
126. Hotta N, Tagaya T, Maeno T, et al. Advanced dynamic flow Imaging with contrast-enhanced ultrasonography for the evaluation of tumor vascularity in liver tumors. Clin Imaging 2005; 29: 34-41
127. Kobayashi S, Maruyama H, Okugawa H, et al. Contrast-enhanced US with Levovist for the diagnosis of hepatic hemangioma: Time-related changes of enhancement appearance and the hemodynamic background. Hepatogastroenterology 2008; 55: 1222-1228
128. 128) Brannigan M, Burns P, Wilson S. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics 2004; 24: 921-935 (Pubitemid 38943326)
129. Wilson SR, Burns PN, Muradali D, et al. Harmonic hepatic US with microbubble contrast agent: Initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 2000; 215: 153-161
130. Basilico R, Blomley MJ, Harvey CJ, et al. Which continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent? Eur J Radiol 2002; 41: 184-191
131. Jang HJ, Kim TK, Burns PN, et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244: 898-906
132. Giorgio A, Ferraioli G, Tarantino L, et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: Comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004; 183: 1319-1326
133. Ding H, Wang WP, Huang BJ, et al. Imaging of focal liver lesions-Low-mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005; 24: 285-297
134. Ricci P, Laghi A, Cantisani V, et al. Contrast-enhanced sonography with SonoVue: Enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2005; 184: 821-827
135. 135) Celli N, Gaiani S, Piscaglia F, et al. Characterization of liver lesions by real-time contrast-enhanced ultrasonography. Eur J Gastroenterol Hepatol 2007; 19: 3-14 (Pubitemid 46066862)
136. Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: Characterization with contrast-enhanced ultrasound. Eur J Radiol 2008 sep.
137. Dai Y, Chen MH, Fan ZH, et al. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Res 2008; 38: 281-290
138. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104
139. Yoshizumi H, Maruyama H, Okugawa H, et al. How to characterize non-hypervascular hepatic nodules on contrast-enhanced computed tomography in chronic liver disease: feasibility of contrast-enhanced ultrasound with a microbubble contrast agent. J Gastroenterol Hepatol 2008; 23: 1528-1534
140. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48: 848-857
141. Inoue T, Kudo M, Watai R, et al. Differential diagnosis of nodular lesions in cirrhotic liver by postvascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2005; 40: 1139-1147
142. Choi D, Lim HK, Kim SH, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: Usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 2000; 217: 558-563
143. Solbiati L, Goldberg SN, Ierace T, et al. Radio-frequency ablation of hepatic metastases: Postprocedural assessment with a US microbubble contrast agent-Early experience. Radiology 1999; 211: 643-649
144. Liu JB, Goldberg BB, Merton DA, et al. The role of contrast-enhanced sonography for radiofrequency ablation of liver tumors. J Ultrasound Med 2001; 20: 517-523
145. Cioni D, Lencioni R, Rossi S, et al. Radiofrequency thermal ablation of hepatocellular carcinoma: Using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. Am J Roentgenol 2001; 177: 783-788
146. Choi D, Lim HK, Lee WJ, et al. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma-Utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 2003; 22: 1163-1172
147. Wen YL, Kudo M, Zheng RQ, et al. Radiofrequency ablation of hepatocellular carcinoma: Therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 181: 57-63
148. Meloni MF, Goldberg SN, Livraghi T, et al. Hepatocellular carcinoma treated with radiofrequency ablation: Comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 2001; 177: 375-380
149. Numata K, Morimoto M, Ogura T, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med 2008; 27: 395-406
150. Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med 2007; 26: 1055-1063
151. Solbiati L, Ierace T, Tonolini M, et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004; 51: S19-S23
152. Leen E, Kumar S, Khan S, et al. Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gastroenterol 2009; 15: 289-299
153. Tsujimoto F, Abe T, Murakami Y, et al. Temporal changes in internal echoes in hepatic hemangiomas. Nippon Acta Radiologica 1989; 49: 574-582
154. Dietrich C, Mertens J, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45: 1139-1145
155. Wilson SR, Kim TK, Jang HJ, et al. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol 2007; 189: W7-W12
156. Murphy-Lavallee J, Jang HJ, Kim TK, et al. Are metastases really hypovascular in the arterial phase? The perspective based on contrast-enhanced ultrasonography. J Ultrasound Med 2007; 26: 1545-1556
157. Piscaglia F, Corradi F, Mancini M, et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. Bmc Cancer 2007; 7
158. Attal P, Vilgrain V, Brancatelli G, et al. Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. Radiology 2003; 228: 465-472
159. Iijima H, Suzuki S, Moriyasu F, et al. Visualization of the drainage veins with contrast-enhanced sonography was useful in diagnosis of small focal nodular hyperplasia. J Ultrasound Med 2006; 25: 799-803
160. Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78: 704-707
161. Kim TK, Jang HJ, Burns PN, et al. Focal nodular hyperplasia and hepatic adenoma: Differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol 2008; 190: 58-66
162. Yen YH, Wang JH, Lu SN, et al. Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol 2006; 60: 439-444
163. 167) Fukukura Y, Nakashima O, Kusaba A, et al. Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. Journal of Hepatology 1998; 29: 470-475 (Pubitemid 28396666)
164. 168) Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5: 1194-1200 (Pubitemid 16222291)
165. Zhou X, Strobel D, Haensler J, et al. Hepatic transit time: indicator of the therapeutic response to radiofrequency ablation of liver tumours. Br J Radiol 2005; 78: 433-436
166. Zhou JH, Li AH, Cao LH, et al. Haemodynamic parameters of the hepatic artery and vein can detect liver metastases: assessment using contrast-enhanced ultrasound. Br J Radiol 2008; 81: 113-119
167. Moriyasu F, Ban N, Nishida O, et al. Quantitative measurement of portal blood flow in patients with chronic liver disease using an ultrasonic Duplex system consisting of a pulsed Doppler flowmeter and B-mode electroscanner. Gastroenterol Jpn 1984; 19: 529-536
168. Moriyasu F, Nishida O, Ban N, et al. Measurement of portal vascular resistance in patients with portal hypertension. Gastroenterology 1986; 90: 710-717
169. 173) Hamato N, Moriyasu F, Someda H, et al. Clinical application of hepatic venous hemodynamics by Doppler ultrasonography in chronic liver disease. Ultrasound Med Biol 1997; 23: 829-835 (Pubitemid 27349530)
170. 174) Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transittime analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583 (Pubitemid 29219208)
171. 175) Bang N, Nielsen MB, Rasmussen AN, et al. Hepatic vein transit time of an ultrasound contrast agent: simplified procedure using pulse inversion imaging. Br J Radiol 2001; 74: 752-755 (Pubitemid 32791550)
172. Blomley MJ, Lim AK, Harvey CJ, et al. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52: 1188-1193
173. Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133
174. 178) Lim AK, Patel N, Eckersley RJ, et al. Hepatic vein transit time of SonoVue: A comparative study with Levovist. Radiology 2006; 240: 130-135 (Pubitemid 43902602)
175. Ridolfi F, Abbattista T, Marini F, et al. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 2007; 39: 929-935
176. Searle J, Mendelson R, Zelesco M, et al. Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study. J Med Imaging Radiat Oncol 2008; 52: 130-133
177. Blomley MJ, Albrecht H, Cosgrove DO, et al. Liver vascular transit time analyzed with dynamic hepatic venography with bolus injections of an US contrast agent: Early experience in seven patients with metastases. Radiology 1998; 209: 862-866
178. Maruyama H, Matsutani S, Okugawa H, et al. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of levovist. Ultrasound Med Biol 2006; 32: 1809-1815
179. Iijima H, Moriyasu F, Tsuchiya K, et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 722-730
180. Arita J, Kokudo N, Zhang KM, et al. Three-dimensional visualization of liver segments on contrast-enhanced intraoperative sonography. AJR Am J Roentgenol 2007; 188: W464-W466
181. Xu HX, Lu MD, Xie XH, et al. Three-dimensional contrast-enhanced ultrasound of the liver: Experience of 92 cases. Ultrasonics 2008
182. Rahbin N, Siosteen AK, Elvin A, et al. Detection and characterization of focal liver lesions with contrast-enhanced ultrasonography in patients with hepatitis C-induced liver cirrhosis. Acta Radiol 2008; 49: 251-257
183. Kratzer W, Schmidt SA, Mittrach C, et al. Contrast-enhanced wideband harmonic imaging ultrasound (SonoVue): A new technique for quantifying bowel wall vascularity in Crohn's disease. Scand J Gastroenterol 2005; 40: 985-991
184. 188) Serra C, Menozzi G, Labate AMM, et al. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol 2007; 62: 114-121 (Pubitemid 46413629)
185. Tawada K, Yamaguchi T, Kobayashi A, et al. Changes in tumor vascularity depicted by contrast-enhanced ultrasonography as a predictor of chemotherapeutic effect in patients with unresectable pancreatic cancer. Pancreas 2009; 38: 30-35
186. Dietrich C, Ignee A, Braden B, et al. Improved differentiation of pancreatic tumors using contrast-enhanced endoscopic ultrasound. Clin Gastroenterol Hepatol 2008; 6: 590-597
187. Kitano M, Sakamoto H, Matsui U, et al. A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video). Gastrointest Endosc 2008; 67: 141-150
188. Itoh T, Hirooka Y, Itoh A, et al. Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 2005; 100: 144-152
189. Kitano M, Kudo M, Maekawa K, et al. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004; 53: 854-859
190. Sofuni A, Iijima H, Moriyasu F, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005; 40: 518-525
191. 195) Zheng HR, Mukdadi S, Shandas R. Theoretical predictions of harmonic generation from submicron ultrasound contrast agents for nonlinear biomedical ultrasound imaging. Phys Med Biol 2006; 51: 557-573 (Pubitemid 43139104)
192. Couture O, Bevan PD, Cherin E, et al. Investigating perfluorohexane particles with high-frequency ultrasound. Ultrasound Med Biol 2006; 32: 73-82
193. Lanka B, Jang HJ, Kim TK, et al. Impact of contrast-enhanced ultrasonography in a tertiary clinical practice. J Ultrasound Med 2007; 26: 1703-1714